Low bone mineral density with tenofovir: does statistically significant mean clinically significant?
Carr
Andrew
A
Hoy
Jennifer
J
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology*; D001847:Bone Diseases / Q000139:chemically induced* / Q000453:epidemiology; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D008297:Male; D063065:Organophosphonates / Q000009:adverse effects*; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine